Efficacy of linezolid alone and in combination with rifampin in staphylococcal experimental foreign-body infection

Journal of Infection

Volumn 57, Issue 3, 2008, Pages 229-235

  Murillo, Oscar ^a   Domenech, Alejandro ^a   Euba, Gorane ^a   Verdaguer, Ricard ^b   Tubau, Fe ^b   Cabo, Javier ^b   Cabellos, Carmen ^a   Gudiol, Francesc ^a   Ariza, Javier ^a  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Animal models; Device infection; Linezolid; Rifampin; S. aureus

Indexed keywords

CLOXACILLIN; LINEZOLID; RIFAMPICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEVICE INFECTION; DRUG EFFICACY; FOREIGN BODY; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PHARMACODYNAMICS; PROTECTION; RAT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREATMENT DURATION;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FOREIGN BODIES; MALE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; OXAZOLIDINONES; RATS; RIFAMPIN; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 50449105682     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2008.07.003     Document Type: Article

References (29)

1. Costerton J.W., Stewart P., and Greenberg E.P. Bacterial biofilm: a common cause of persistent infections. Science 284 (1999) 1318-1322
2. Chuard C., Lucet J.C., Rohner P., Herrmann M., Auckentaler R., Waldvogel F.A., et al. Resistance of Staphylococcus aureus recovered from infected foreign body in vivo to killing by antimicrobials. J Infect Dis 163 (1991) 1369-1373
3. Stewart P.S., and Costerton J.W. Antibiotic resistance of bacteria in biofilms. Lancet 358 (2001) 135-138
4. Zimmerli W., Trampuz A., and Ochsner P.E. Prosthetic-joint infections. N Engl J Med 351 (2004) 1645-1654
5. Zimmerli W., Widmer A.F., Blatter M., Frei R., and Ochsner P.E. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections. JAMA 279 (1998) 1537-1541
6. Widmer A.F., Frei R., Rajacic Z., and Zimmerli W. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J Infect Dis 162 (1990) 96-102
7. Zimmerli W., Frei R., Widmer A.F., and Rajacic Z. Microbiological test to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J Antimicrob Chemother 33 (1994) 959-967
8. Widmer A.F., Gaechter A., Ochsner P.E., and Zimmerli W. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin Infect Dis 14 (1992) 1251-1253
9. Eng R.H., Smith S.M., Tillem M., and Cherubin C. Rifampin resistance. Development during the therapy of methicillin-resistant Staphylococcus aureus infection. Arch Intern Med 145 (1985) 146-148
10. Drancourt M., Stein A., Argenson J.N., Zannier A., Curvale G., and Raoult D. Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants. Antimicrob Agents Chemother 37 (1993) 1214-1218
11. Drancourt M., Stein A., Argenson J.N., Roiron R., Groulier P., and Raoult D. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampin. J Antimicrob Chemother 39 (1997) 235-240
12. Chien J.W., Kucia M.L., and Salata R.A. Use of linezolid, an oxazolidinone in the treatment of multidrug-resistant gram-positive bacterial infections. Clin Infect Dis 30 (2000) 146-151
13. Bassetti M., Vitale F., Melica G., Righi E., Di Bagio A., Molfetta L., et al. Linezolid in the treatment of gram-positive prosthetic joint infections. J Antimicrob Chemother 55 (2005) 387-390
14. Jover-Saenz A., Gaite F.B., Ribelles A.G., Porcel-Perez J.M., and Garcia-Calvo S. Linezolid treatment of total prosthetic knee infection due to methicillin-resistant Staphylocococcus epidermidis. J Infect 47 (2003) 87-88
15. Bassetti M., Di Biagio A., Cenderello G., Del Bono V., Palermo A., Cruciani M., et al. Linezolid treatment of prosthetic infections due to methicillin-resistant Staphylocococcus aureus. J Infect 43 (2001) 148-149
16. Soriano A., Gómez J., Gómez L., Azanza J.R., Perez R., Romero F., et al. Efficacy and tolerability of prolonged linezolid therapy in the treatment of orthopedic implant infections. Eur J Clin Microbiol Infect Dis 26 (2007) 353-356
17. Lucet J.C., Herrmann M., Rohner P., Auckenthaler R., Waldvogel F.A., and Lew D.P. Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 34 (1990) 2312-2317
18. Chuard C., Herrmann M., Vaudaux P., Waldvogel F.A., and Lew D.P. Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob Agents Chemother 35 (1991) 2611-2616
19. Schaad H.J., Chuard C., Vaudaux P., Rohner P., Waldvogel F.A., and Lew D.P. Comparative efficacies of imipenem, oxacillin and vancomycin for therapy of chronic foreign body infection due to methicillin-susceptible and -resistant Staphylococcus aureus. J Antimicrob Chemother 33 (1994) 1191-1200
20. Vaudaux P., Francois P., Bisognano C., Schrenzel J., and Lew D.P. Comparison of levofloxacin, alatrofloxacin and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 46 (2002) 1503-1509
21. Murillo O., Doménech A., García A., Tubau F., Cabellos C., Gudiol F., et al. Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylocococcus aureus. Antimicrob Agents Chemother 50 (2006) 4011-4017
22. Clinical and Laboratory Standards Institute, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed. Approved Standard M7-A6 (2005), CLSI, Wayne, Pennsylvania, USA
23. National Comittee for Clinical Laboratory Standards, Methods for determining bactericidal activity of antimicrobial agents M26-A (1999), NCCLS, Villanova, PA, USA
24. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26 (1998) 1-12
25. Ryan M., Hodges B., Spencer G.R., and Harding S.M. Simultaneous comparison of three methods for assessing ceftazidime penetration into extravascular fluid. Antimicrob Agents Chemother 22 (1982) 995-998
26. Trampuz A., Wenk M., Rajacic Z., and Zimmerli W. Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid. Antimicrob Agents Chemother 44 (2000) 1352-1355
27. Jacqueline C., Caillon J., Le Mabecque V., Miegeville A.F., Donnio P.Y., Bugnon D., et al. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J Antimicrob Chemother 51 (2003) 857-864
28. Grohs P., Kitzis M., and Gutmann L. In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother 47 (2003) 418-420
29. Soriano A., Jurado A., Marco F., Almela M., Ortega M., and Mensa J. In vitro activity of linezolid, moxifloxacin, levofloxacin, clindamycin and rifampin, alone and in combination, against Staphylococcus aureus and Staphylococcus epidermidis. Rev Esp Quimioterap 18 (2005) 168-172